Myra Vision, Inc. is a clinical-stage ophthalmic medical device company headquartered in Campbell, California, and a privately held portfolio company of the Shifamed LLC medical device incubator. It develops the Calibreye Titratable Glaucoma Therapy (TGT) Surgical System, an aqueous shunt for patients with moderate to severe glaucoma whose valve-controlled outflow channels use shape-memory nitinol and can be reversibly opened or closed in-office with a transcorneal laser, letting a clinician titrate intraocular pressure after implantation rather than committing to a fixed flow at the time of surgery. The company completed first-in-human use of the Calibreye System in 2023, received FDA conditional approval of its Investigational Device Exemption in August 2025, and enrolled the first patient in its US ADAPT clinical study in January 2026. As a medical device manufacturer its product is a physical implant and a surgical procedure, not software: Myra Vision publishes no public developer API, SDK, developer portal, or machine-readable API specification, and this profile captures its corporate identity and public web properties in the API Evangelist network.
Myra Vision is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Healthcare, Ophthalmology, and Glaucoma.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Show this score on your site.
It updates itself when the score changes. Paste this where you link to your API docs:
<a href="https://apis.io/providers/myra-vision/"><img src="https://apis.io/badge/myra-vision/card.svg" alt="Myra Vision on APIs.io — Kin Score by API Evangelist"></a>
Other styles, a README pill and a shields.io endpoint are on the badge page.
Raise your score.
Agent readiness — checks not met, largest first (exact, from this profile):
Machine-Readable Auth+10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey)
Idempotency+9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented)
Stable Error Semantics+8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes
13 more unmet checks in the Agent Readiness table above.
Kin Score — facets with the most composite points still available (weight × headroom):
aid: myra-vision
name: Myra Vision
description: 'Myra Vision, Inc. is a clinical-stage ophthalmic medical device company headquartered in Campbell, California,
and a privately held portfolio company of the Shifamed LLC medical device incubator. It develops the Calibreye Titratable
Glaucoma Therapy (TGT) Surgical System, an aqueous shunt for patients with moderate to severe glaucoma whose valve-controlled
outflow channels use shape-memory nitinol and can be reversibly opened or closed in-office with a transcorneal laser, letting
a clinician titrate intraocular pressure after implantation rather than committing to a fixed flow at the time of surgery.
The company completed first-in-human use of the Calibreye System in 2023, received FDA conditional approval of its Investigational
Device Exemption in August 2025, and enrolled the first patient in its US ADAPT clinical study in January 2026. As a medical
device manufacturer its product is a physical implant and a surgical procedure, not software: Myra Vision publishes no public
developer API, SDK, developer portal, or machine-readable API specification, and this profile captures its corporate identity
and public web properties in the API Evangelist network.'
url: https://raw.githubusercontent.com/api-evangelist/myra-vision/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
probe_state: none
source:
- security
generated: '2026-11-06'
method: derived
specificationVersion: '0.23'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Medical Devices
- Healthcare
- Ophthalmology
- Glaucoma
- Life Sciences
- Medical Technology
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/myra-vision-domain-security.yml
- type: Website
url: https://www.myravision.com/
- type: PrivacyPolicy
url: https://www.myravision.com/privacy-policy/
- type: LinkedIn
url: https://www.linkedin.com/company/myra-vision
x-enrichment:
date: '2026-08-04'
status: minimal
artifacts_added: 1
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Myra Vision is a 25-person clinical-stage medical device maker whose product is the Calibreye titratable glaucoma
shunt — a nitinol implant adjusted in-office by laser, not software; its entire web presence is a five-page WordPress
marketing site (home, sign-up, privacy policy, titratable-outflow, 404) with no developer, docs, or api subdomain resolving
in DNS, no GitHub organization, and no package on npm/PyPI, and the origin additionally answers every path with a SiteGround
captcha challenge (HTTP 202) so live /.well-known and /openapi.json probes were confirmed against archived crawls instead.
evidence:
- url: https://www.myravision.com/
status: 202
- url: https://www.myravision.com/openapi.json
status: 202
- url: https://web.archive.org/web/20250305100237id_/https://www.myravision.com/page-sitemap.xml
status: 200
- url: https://web.archive.org/web/20250306013206/https://www.myravision.com/.well-known/security.txt
status: 404
- url: https://api.github.com/orgs/myravision
status: 404
checked: '2026-08-04'
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.